#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15294	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2033	745.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1744	1744	T	842	T	783	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15294	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2033	745.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1478	1478	C	881	C	811	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15294	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2033	745.9	0	HET	.	.	.	C136CGGGGG,CGGGGGG	.	136	136	C	430	430	C	851	CGGGGG,CGGGGGG	621,140	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27634	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3522	782.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1655	1655	A	960	A,G	895,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27634	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3522	782.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2289	2289	C	889	C,T	823,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27634	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3522	782.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2363	2363	A	886	A	842	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27634	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3522	782.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	2915	2915	C	807	C	750	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27634	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3522	782.4	0	HET	.	.	.	C265T	.	265	265	C	583	583	C	913	C,T	601,136	.	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	16	8	blaTEM	861	188	100.0	blaTEM.l15.c4.ctg.1	188	2.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	27	2074	folP	852	852	100.0	folP.l15.c17.ctg.1	1423	145.0	1	SNP	p	R228S	1	.	.	682	684	AGC	948	950	AGC	204;207;206	A;G;C	186;189;186	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5694	gyrA	2751	2751	100.0	gyrA.l15.c30.ctg.1	3366	168.7	1	SNP	p	S91F	0	.	.	271	273	TCC	532	534	TCC	184;185;186	T;C;C	173;172;174	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5694	gyrA	2751	2751	100.0	gyrA.l15.c30.ctg.1	3366	168.7	1	SNP	p	D95N	0	.	.	283	285	GAC	544	546	GAC	174;174;175	G;A,G;C	163;162,1;164	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5694	gyrA	2751	2751	100.0	gyrA.l15.c30.ctg.1	3366	168.7	1	SNP	p	D95G	0	.	.	283	285	GAC	544	546	GAC	174;174;175	G;A,G;C	163;162,1;164	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1632	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1173	138.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	367	369	ACC	201;200;198	A;C;C	175;182;180	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1632	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1173	138.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	382	384	CAC	199;199;203	C;A;C	182;178;186	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1632	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1173	138.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	565	567	CAC	231;229;230	C;A;C	208;209;207	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1632	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1173	138.1	1	SNP	p	G45D	0	.	.	133	135	GGC	385	387	GGC	202;202;203	G;G;C	185;183;184	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	912	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1104	82.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5136	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3012	170.0	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1507	1509	ATC	200;205;203	A;T;C	185;190;190	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5136	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3012	170.0	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1660	1662	GCA	209;207;208	G;C;A	192;189;189	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5136	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3012	170.0	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2143	2145	ATT	216;219;220	A;T;T	200;204;205	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5136	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3012	170.0	1	SNP	p	D86N	0	.	.	256	258	GAC	613	615	GAC	199;202;206	G;A;C	187;191;195	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5136	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3012	170.0	1	SNP	p	S87W	0	.	.	259	261	AGT	616	618	AGT	205;203;204	A;G;T	191;189;191	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5136	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3012	170.0	1	SNP	p	S87I	0	.	.	259	261	AGT	616	618	AGT	205;203;204	A;G;T	191;189;191	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5136	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3012	170.0	1	SNP	p	S87R	0	.	.	259	261	AGT	616	618	AGT	205;203;204	A;G;T	191;189;191	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5136	parC	2304	2304	99.74	parC.l15.c4.ctg.1	3012	170.0	1	SNP	p	S88P	0	.	.	262	264	TCC	619	621	TCC	203;203;206	T;C;C	190;188;192	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4566	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2497	181.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1446	1448	GGC	180;177;175	G;G;C	166;166;161	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.15.001	penA.15.001	1	1	27	4340	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2450	176.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1295	1297	GCA	232;233;235	G;C;A	219;217;222	penA.15.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4340	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2450	176.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1298	1300	ATC	240;240;245	A;T;C	225;225;229	penA.15.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4340	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2450	176.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1310	1312	GTG	249;245;247	G;T;G	236;229;233	penA.15.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4340	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2450	176.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1310	1312	GTG	249;245;247	G;T;G	236;229;233	penA.15.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4340	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2450	176.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1811	1813	ACC	213;216;217	A;C;C	198;204;205	penA.15.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4340	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2450	176.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1865	1867	GCG	221;218;214	G;C;G	181;174;172	penA.15.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4340	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2450	176.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1865	1867	GCG	221;218;214	G;C;G	181;174;172	penA.15.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4340	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2450	176.6	1	SNP	p	G542S	0	.	.	1624	1626	GGC	1988	1990	GGC	169;166;166	G;G;C	150;146;146	penA.15.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4340	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2450	176.6	1	SNP	p	G545S	0	.	.	1633	1635	GGC	1997	1999	GGC	169;166;169	G;G;C	148;143;145	penA.15.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.15.001	penA.15.001	1	1	27	4340	penA	1746	1746	100.0	penA.l6.c30.ctg.1	2450	176.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2015	2017	CCG	148;152;153	C,G;C;G	107,2;114;112	penA.15.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	6162	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3198	192.2	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1612	1614	CTG	246;249;252	C;T;G	221;224;227	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2306	porA	1146	1146	99.65	porA.l15.c30.ctg.1	1656	137.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	568	568	C	159	C	146	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	306	porB1a	984	282	90.91	porB1a.l15.c30.ctg.2	368	26.6	0	.	p	.	0	D238fs	FSHIFT	712	712	G	18	18	G	11	G	4	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	G46D	NONSYN	136	138	GGC	377	379	GAC	234;230;234	G;A;C	218;219;221	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	383	385	GGA	235;235;238	G;G;A	220;217;223	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	E134K	NONSYN	400	402	GAG	641	643	AAG	235;231;234	A;A;G	218;216;218	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	F135L	NONSYN	403	405	TTT	644	646	CTT	233;236;238	C;T;T	217;220;221	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	668	670	GGA	246;243;245	G;G;A	223;220;220	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	G189S	NONSYN	565	567	GGC	806	808	AGC	247;247;247	A;G,A;C	231;232,1;229	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	Y211_N212insDGQ	INS	631	631	T	872	872	T	230	T	210	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	N212_S213insL	INS	634	634	A	885	885	C	226	C	212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	I214M	NONSYN	640	642	ATC	893	895	ATG	232;232;231	A;T;G	215;216;213	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	L218F	NONSYN	652	654	CTT	905	907	TTT	235;236;241	TTTGTTG,TTTG;T;T	226,1;221;226	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	A238V	NONSYN	712	714	GCC	965	967	GTT	251;253;259	G;T;T	235;236;241	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	T252A	NONSYN	754	756	ACA	1007	1009	GCA	236;234;231	G;C,G;A	219;216,1;214	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	W253T	NONSYN	757	759	TGG	1010	1012	ACG	226;224;225	A;C;G	209;210;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	S254R	NONSYN	760	762	AGT	1013	1015	AGG	224;220;216	A;G;G	209;208;205	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	A255V	NONSYN	763	765	GCT	1016	1018	GTT	214;211;213	G;T;T	207;203;206	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	L275V	NONSYN	823	825	TTA	1076	1078	GTA	229;230;231	G;T;A	212;213;213	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	S288T	NONSYN	862	864	TCT	1115	1117	ACT	256;257;257	A;C;T	229;236;235	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	H290D	NONSYN	868	870	CAT	1121	1123	GAT	261;259;259	G;A;T	238;237;238	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	S291D	NONSYN	871	873	AGT	1124	1126	GAT	253;252;252	G;A;T	231;231;231	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	D293N	NONSYN	877	879	GAC	1130	1132	AAC	250;247;247	A;A;C	232;227;226	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	Y294H	NONSYN	880	882	TAC	1133	1135	CAC	249;247;248	C;A;C	229;227;227	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	0	.	p	.	0	E329D	NONSYN	985	987	GAA	1238	1240	GAC	251;249;246	G;A;C	235;232;229	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	1	SNP	p	G120K	0	.	.	358	360	GGT	599	601	GGT	226;226;229	G;G;T	208;206;207	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	1	SNP	p	A121N	0	.	.	361	363	GCC	602	604	GCC	232;231;230	G;C;C	210;210;213	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2962	porB1b	1035	1035	96.28	porB1b.l6.c17.ctg.1	1439	204.4	1	SNP	p	A121D	0	.	.	361	363	GCC	602	604	GCC	232;231;230	G;C;C	210;210;213	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11780	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4835	243.1	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1993	1995	CAT	277;274;277	C;A,G;T	251;250,1;252	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1286	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1060	121.0	1	SNP	p	V57M	0	.	.	169	171	GTG	526	528	GTG	253;252;254	G;T;G	234;235;236	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
